Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID‐19 convalescent plasma clinical trial

Madariaga, Maria Lucia; Guthmiller, Jenna J.; Schrantz, Stephen; Jansen, Maud O.; Christensen, Chancey; Kumar, Madan; Prochaska, Micah T.; Wool, Geoffrey D.; Durkin‐Celauro, Amy; Oh, Won H.; Trockman, Laura; Vigneswaran, Janani; Keskey, Robert; Shaw, Dustin G.; Dugan, Haley L.; Zheng, Na; Cobb, Mari; Utset, Henry A.; Wang, Jiaolong; Stovicek, Olivia; Bethel, Cindy; Matushek, Scott; Giurcanu, Mihai; Beavis, Kathleen G.; Sabato, Diego di; Meltzer, David; Ferguson, Mark K.; Kress, John P.; Shanmugarajah, Kumaran; Matthews, Jeffrey B.; Fung, John; Wilson, Patrick C.; Alverdy, John C.; Donington, Jessica S.

doi:10.1111/joim.13185

Cited by 43 publications

(52 citation statements)

References 36 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following removing duplicates and screening of titles and abstracts, we evaluated 153 articles in full text. Among these, we found 45 relevant articles (4RCTs, 11 controlled NRSIs, 7 non-controlled NRSIs and 23 case reports) [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] . Extracted details are presented in Table 1 (RCTs, controlled NRSIs, and non-controlled NRSIs) and table 2 (case report(series)).…”

Section: Resultsmentioning

confidence: 99%

“…Pre-screening of CP may be necessary for selecting donors with high levels of neutralizing activity for infusion into patients with COVID-19. No study-related serious AEs Madariaga MD et al [42] USA Open label clinical study Intervention 10 Severe or life-threatening ~300 ml Within 21 days RBD range from 0 to 1:3289 Remdesivir, tocilizumab, anakinra and HCQ. Despite variability in donor titer, 80% of recipients showed significant increase in antibody levels post-transfusion.…”

Section: Resultsmentioning

confidence: 99%

“…The patients included in the study had a wide range of age distribution, ranged from 4 to 100 years old. The patients’ conditions were variable, two RCTs [21] , [24] and three controlled NRSIs [26] , [28] , [33] included moderate to severely ill patients, one RCT included less-severe patients, and the clinical symptoms of patients in the 6 controlled NRSIs met the definitions of severe or life-threatening disease [29] , [31] , [32] , [37] , [41] , [42] . One RCT [22] and 4 controlled NRSIs [27] , [34] , [35] , [40] evaluated CP therapy in critically ill individuals.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Wang

Huo

Dai

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Wang

Huo

Dai

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

“…Limited previous clinical experiences with CP treatment in SARS-CoV, MERS, influenza, and Ebola suggest that CP may provide benefits to COVID-19 patients (Bloch et al, 2020;Devasenapathy et al, 2020). Many recent reports have documented clinical outcomes of CP treatment in severe and critically ill COVID-19 patients (Ahn et al, 2020;Ibrahim et al, 2020;Jin et al, 2020;Keith et al, 2020;Li et al, 2020a;Li et al, 2020b;Liu et al, 2020a;Madariaga et al, 2020;Maor et al, 2020;Pei et al, 2020;Perotti et al, 2020;Dwi Putera and Suci Hardianti, 2020;Shen et al, 2020a;Wang et al, 2020c;Ye et al, 2020a;Zhang et al, 2020a). Two categories of results are presented.…”

Section: Convalescent Plasma and Ivig Treatment Of Covid-19 Patientsmentioning

confidence: 99%

“…First, the strength of the data is limited by the sample size. Among the above studies, 11 reported CP treatment in 10 or less COVID-19 patients (Ahn et al, 2020;Duan et al, 2020;Jin et al, 2020;Keith et al, 2020;Li et al, 2020a;Madariaga et al, 2020;Pei et al, 2020;Shen et al, 2020a;Wang et al, 2020c;Ye et al, 2020a;Zhang et al, 2020a). Five studies treated 37-49 patients (Ibrahim et al, 2020;Liu et al, 2020a;Maor et al, 2020;Perotti et al, 2020;Dwi Putera and Suci Hardianti, 2020).…”

Section: Convalescent Plasma and Ivig Treatment Of Covid-19 Patientsmentioning

confidence: 99%

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Zhang

Zhan

et al. 2020

Sci. China Life Sci.

View full text Add to dashboard Cite

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients’ outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

show abstract

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

et al. 2023

View full text Add to dashboard Cite

ImportancePatients who are immunocompromised have increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently mount antibody responses to vaccines. Although neutralizing anti-spike monoclonal-antibody treatment has been widely used to treat COVID-19, evolutions of SARS-CoV-2 have been associated with monoclonal antibody-resistant SARS-CoV-2 variants and greater virulence and transmissibility of SARS-CoV-2. Thus, the therapeutic use of COVID-19 convalescent plasma has increased on the presumption that such plasma contains potentially therapeutic antibodies to SARS-CoV-2 that can be passively transferred to the plasma recipient.ObjectiveTo assess the growing number of reports of clinical experiences of patients with COVID-19 who are immunocompromised and treated with specific neutralizing antibodies via COVID-19 convalescent plasma transfusion.Data SourcesOn August 12, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma use in patients who are immunocompromised.Study SelectionRandomized clinical trials, matched cohort studies, and case report or series on COVID-19 convalescent plasma use in patients who are immunocompromised were included. The electronic search yielded 462 unique records, of which 199 were considered for full-text screening.Data Extraction and SynthesisThe study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were extracted by 3 independent reviewers in duplicate and pooled.Main Outcomes and MeauresThe prespecified end point was all-cause mortality after COVID-19 convalescent plasma transfusion; exploratory subgroup analyses were performed based on putative factors associated with the potential mortality benefit of convalescent plasma.ResultsThis systematic review and meta-analysis included 3 randomized clinical trials enrolling 1487 participants and 5 controlled studies. Additionally, 125 case series or reports enrolling 265 participants and 13 uncontrolled large case series enrolling 358 participants were included. Separate meta-analyses, using models both stratified and pooled by study type (ie, randomized clinical trials and matched cohort studies), demonstrated that transfusion of COVID-19 convalescent plasma was associated with a decrease in mortality compared with the control cohort for the amalgam of both randomized clinical trials and matched cohort studies (risk ratio [RR], 0.63 [95% CI, 0.50-0.79]).Conclusions and RelevanceThese findings suggest that transfusion of COVID-19 convalescent plasma is associated with mortality benefit for patients who are immunocompromised and have COVID-19.

show abstract

Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID‐19 convalescent plasma clinical trial

Cited by 43 publications

References 36 publications

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About